News Releases

News Releases

March 06, 2019
Mar
06
2019

Ordinary Shares Will Begin Trading on a Split-Adjusted Basis on March 6, 2019 Tel Aviv, Israel , March 06, 2019 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (NasdaqCM: ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced the effectiveness of an eight to one reverse split of...

Continue reading

February 19, 2019
Feb
19
2019

Unconditional payment of $3.5 million Contingent payment of up to additional $17 million plus royalties Seelos to receive rights also to the Trehalose for Sanfilippo Syndrome Program Tel Aviv, Israel , Feb. 19, 2019 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd....

Continue reading

February 14, 2019
Feb
14
2019

Tel Aviv, Israel , Feb. 14, 2019 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (NasdaqCM: ORPN) (“Bioblast”), a clinical-stage, orphan disease-focused biotechnology company, and Team Sanfilippo (“TSF”), a nonprofit medical research foundation founded by parents of children with Sanfilippo Syndrome today...

Continue reading

January 11, 2019
Jan
11
2019

Tel Aviv, Israel , Jan. 11, 2019 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (NasdaqCM: ORPN) (“Bioblast” or the “Company”), a clinical-stage, orphan disease-focused biotechnology company, announced today that it received a written notification from the Listing Qualifications Department of The Nasdaq...

Continue reading

November 19, 2018
Nov
19
2018

Enlivex Therapeutics is a private, venture-funded clinical stage immunotherapy company developing an allogeneic drug pipeline for immune system rebalancing, which is critical for the treatment of life-threatening immune and inflammatory conditions that involve the hyper-expression of cytokines...

Continue reading

July 26, 2018
Jul
26
2018

<p>TEL AVIV, Israel and NEW YORK , July 26, 2018 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN) is providing an update on business development activities as well as notice of an organization change that affects members of the board and management.</p> ...

Continue reading

November 02, 2017
Nov
02
2017

TEL AVIV, Israel , Nov. 02, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced financial results for the third quarter ended September 30, 2017 . Third Quarter 2017 Financial Results and Cash Position R&amp;D...

Continue reading

September 25, 2017
Sep
25
2017

Ordinary Shares Will Begin Trading on a Split-Adjusted Basis on September 25, 2017 TEL AVIV, Israel , Sept. 25, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (NasdaqCM:ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced the effectiveness of a five to one reverse split...

Continue reading